Clinical Trials

ACCRU SC-1601 EVE Trial

A Phase III, Randomized, Open label Study Evaluating the Safety of Apixaban in Subjects with Cancer Related Venous thromboembolism


This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer-related blood clots in cancer patients who have completed anticoagulation therapy. Apixaban may stop the clotting of blood by blocking some of the enzymes needed for blood clotting.

NCT# 03080883


Clinical Trial Categories

  • Other
NH Oncology Hematology Clinical Research Dept. at (603) 224-2556


  • Payson Center for Cancer Care
    Concord Hospital
    250 Pleasant Street
    Concord, NH 03301
    Main: (603) 230-6000